journal article·2020-06-29Open access

Platelet-Rich Plasma (PRP) in Dental Extraction of Patients at Risk of Bisphosphonate-Related Osteonecrosis of the Jaws: A Two-Year Longitudinal Study

Rodolfo Mauceri, Vera Panzarella, Giuseppe Pizzo, Giacomo Oteri, Gabriele Cervino, Giuseppina Mazzola, Olga Di Fede, Giuseppina Campisi

Applied Sciences· Volume 10· Issue 13

Abstract

Dental extraction has often been described as the main trigger event of osteonecrosis of the jaws (ONJ). This longitudinal hospital-based study aimed to evaluate the outcome at 2 years of a standardized medical-surgical protocol for dental extraction, combined with platelet rich-plasma (PRP) application, compared with conventional protocol not combined with PRP or any other autologous platelet concentrate in cancer (ONC) and osteometabolic (OST) patients, at risk of bisphosphonate (BP)-related ONJ. Twenty patients were consecutively recruited: six received BPs for cancer skeletal-related events (34.17 ± 19.97 months), while fourteen received BPs for metabolic bone disease (74.5 ± 34.73 months). These patients underwent a standardized protocol for dental extraction, combined with autologous PRP application in the post-extraction socket. A total of 63 dental extractions were performed (24 and 39 in ONC and OST groups, respectively). As controls, historical cases, derived from the literature and including 171 ONC and 734 OST patients, were considered. The outcome of the surgical treatment was successful in all patients treated with PRP: two years after extraction, no patient had clinical or radiological signs of ONJ. When this datum was compared with historical controls, no statistically significant differences were found (p > 0.1). The combination of a standardized medical-surgical protocol with PRP application may contribute to limit the occurrence of BP-related ONJ, in both ONC and OST patients. Additional prospective studies with a larger patient sample are necessary to confirm this datum.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone health and treatments · Bone and Joint Diseases · Cancer Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina; 98125 Messina, Italy

Unit of Transfusion Medicine, University Hospital “Policlinico Paolo Giaccone”, 90127 Palermo, Italy

References (45)

Show source-provided references
1. Bedogni, A., Campisi, G., and Fusco, V. (2018). Medication Related Osteonecrosis of the Jaw (MRONJ), Qeios.10.32388/594095 ↗
2. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents10.2217/fon.13.211 ↗
3. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic10.1016/S0278-2391(03)00720-1 ↗
4. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology10.1080/14740338.2016.1177021 ↗
5. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib10.1016/j.ijom.2019.07.010 ↗
6. Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review10.1007/s00520-018-4501-x ↗
7. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update10.1016/j.joms.2014.04.031 ↗
8. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: A multivariate analysis10.1016/j.ijom.2015.01.014 ↗
9. The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention
10. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice10.1007/s00774-009-0128-9 ↗
11. The influence of zoledronic acid and cyclophosphamide on microcirculation regeneration in healing oral mucosal flaps10.1016/j.archoralbio.2010.11.015 ↗
12. Bisphosphonate-related osteonecrosis of the jaws—Characteristics, risk factors, clinical features, localization and impact on oncological treatment10.1016/j.jcms.2011.05.003 ↗
13. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw10.1016/j.coms.2015.06.005 ↗
14. Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction10.1016/j.jcms.2015.02.018 ↗
15. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?10.1016/j.jcms.2015.03.039 ↗
16. Interventions for managing medication-related osteonecrosis of the jaw
17. Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review
18. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature10.1016/j.ejca.2014.10.015 ↗
19. Platelet-rich plasma (PRP) in dental and oral surgery: From the wound healing to bone regeneration10.1186/1742-4933-10-23 ↗
20. Healing of Postextraction Sockets Preserved With Autologous Platelet Concentrates. A Systematic Review and Meta-Analysis10.1016/j.joms.2017.02.009 ↗
21. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives
22. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery10.2174/138920112800624391 ↗
23. Occurrence of Bisphosphonate-Related Osteonecrosis of the Jaw After Surgical Tooth Extraction10.1016/j.joms.2009.10.026 ↗
24. Preventive protocol for tooth extractions in patients treated with zoledronate: A case series10.1016/j.joms.2010.10.055 ↗
25. Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw10.1016/j.oooo.2012.08.442 ↗
26. Risk of developing BRONJ among patients exposed to intravenous bisphosphonates following tooth extraction
27. Tooth extraction in osteoporotic patients taking oral bisphosphonates10.1007/s00198-012-2239-8 ↗
28. Bedogni, A., Campisi, G., Fusco, V., and Agrillo, A. (2013). Raccomandazioni Clinico-Terapeutiche Sull’osteonecrosi Delle Ossa Mascellari Associata A Bisfosfonati E Sua Prevenzione, Cleup.
29. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)10.1111/j.1601-0825.2012.01903.x ↗
30. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline10.1200/JCO.19.01186 ↗
31. Nicolatou-Galitis, O., Papadopoulou, E., Vardas, E., Kouri, M., Galiti, D., Galitis, E., Alexiou, K., Tsiklakis, K., Ardavanis, A., and Razis, E. (2020). Alveolar bone histological necrosis observed prior to extractions in patients, who received bone targeting agents. Oral Dis.10.1111/odi.13294 ↗
32. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: Report of 5 cases and literature review10.1016/j.oooo.2015.08.007 ↗
33. Soutome, S., Hayashida, S., Funahara, M., Sakamoto, Y., Kojima, Y., Yanamoto, S., and Umeda, M. (2018). Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?. PLoS ONE, 13.10.1371/journal.pone.0201343 ↗
34. Medication-related osteonecrosis of the jaw afte tooth extraction in cancer patients: A multicenter retrospective study10.1007/s00198-018-4746-8 ↗
35. Bisphosphonate-related osteonecrosis of the jaw: A mechanobiology perspective10.1016/j.bonr.2018.03.003 ↗
36. Tooth extraction in patients on zoledronic acid therapy10.1016/j.oraloncology.2012.03.009 ↗
37. Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates10.5624/isd.2017.47.1.45 ↗
38. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis10.1016/j.oraloncology.2011.02.024 ↗
39. Kyrgidis, A., Koloutsos, G., and Vahtsevanos, K. (2009). Treatment protocols of bisphosphonate-related osteonecrosis of the jaws. Head Neck, 1112–1113.10.1002/hed.21148 ↗
40. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: A report of 32 cases10.1016/j.oraloncology.2011.12.004 ↗
41. Platelet Rich Plasma in the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw: Personal Experience and Review of the Literature10.1155/2014/298945 ↗
42. Mauceri, R., Panzarella, V., Maniscalco, L., Bedogni, A., Licata, M.E., Albanese, A., Toia, F., Cumbo, E.M.G., Mazzola, G., and Di Fede, O. (2018). Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er, Cr: YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study. BioMed Res. Int., 2018.10.1155/2018/3982540 ↗
43. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: A trial study10.1007/s00784-016-2004-z ↗
44. Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: A cautionary report10.1016/j.joms.2010.07.026 ↗
45. Tooth extractions in intravenous bisphosphonate-treated patients: A refined protocol10.1016/j.joms.2013.01.006 ↗